Zydus receives final approval from the USFDA for

Aspirin and Extended-Release Dipyridamole Capsules _________________________________________________________________________________

Ahmedabad, 30 August 2017

Zydus Cadila has received the final approval from the USFDA to market Aspirin and

Extended-Release Dipyridamole Capsules in the strength of 25 mg/200 mg. The drug is an

antiplatelet agent which works in the prevention of excessive blood clotting and is used to

reduce the risk of stroke in patients who have had or are at risk of stroke.

The drug will be manufactured at the group’s formulations manufacturing facility at Moraiya,

Ahmedabad. The sales of Aspirin and Extended-Release Dipyridamole Capsules are

estimated at $198.7 million. Source: IMS Health, IMS National Sales Perspective Audit, MAT

July 2017, extracted August 2017.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the

commencement of the filing process in FY 2003-04.

***